Nucleic acid composition, kit and detection method for detecting multiple drug-resistant genes
The multiplex universal LNA probe fluorescence quantitative PCR method solves the problems of long detection cycle, high cost and limited throughput of drug resistance genes in the existing technology, and realizes rapid, accurate and low cost multiplex drug resistance gene detection, which is suitable for clinical samples.
Patent Information
- Application Number
- CN202411138460.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies for detecting drug resistance genes suffer from problems such as long detection cycles, complex operations, poor specificity, high costs, and limited detection throughput, especially when multiple drug resistance mechanisms coexist, making it difficult to achieve rapid and accurate detection.
The multiplex universal LNA probe fluorescence quantitative PCR method (MLQPCR) was adopted. By designing primers and universal LNA probes and combining them with multicolor fluorescence channels, a rapid and sensitive detection of 16 drug resistance genes was achieved, simplifying the operation process and reducing costs.
It enables rapid, accurate, sensitive, and low-cost detection of multiple drug resistance genes, applicable to the detection of all drug resistance genes in clinical samples, reducing detection costs and increasing throughput, avoiding contamination from opening the cap, and ensuring high reliability of results.
Smart Images

Figure CN118932093A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of in vitro diagnostic technology, and in particular to a nucleic acid composition, a kit and a detection method for detecting multiple drug-resistant genes. Background Art
[0002] The problem of microbial resistance has become a focal issue of global public health. The emergence and widespread spread of bacterial resistance poses severe challenges to clinical anti-infection treatment and seriously affects the health of humans and animals. It is reported that in 2019, approximately 5 million deaths were indirectly related to microbial resistance, of which approximately 1.27 million people died directly from microbial resistance. In the face of the problem of drug resistance, if no action is taken, it is estimated that by 2025, 10 million people will die each year from antimicrobial resistance (AMR) worldwide, and the number of deaths may exceed that of tumors. Therefore, rapid clinical identification of pathogens and drug resistance is a prerequisite for reducing the abuse of antibiotics. Advances in drug resistance detection technology can make patients use drugs more accurately and slow the further development of AMR.
[0003] Since the clinical symptoms of infected patients are usually similar, it is difficult for doctors to determine the type of pathogens that infect patients at the first time. With the increase of antibiotic abuse and bacterial resistance, the difficulty of clinical diagnosis and treatment has been further aggravated. Most of the antibiotic prescriptions for patients with microbial infections are based on regional microbial epidemic trends, guideline recommendations or empirical treatment, rather than on the infected microorganisms and resistance types of individual patients. Dynamic monitoring of individual pathogens and drug resistance is the key to guiding the rational use of clinical antibiotics. For patients with severe pneumonia, mixed infections and multidrug resistance are particularly serious, and the distribution of drug resistance genes is also extremely complex. Once the wrong medication is used, it will increase the burden of clinical treatment. Therefore, establishing a rapid, accurate and economical method for detecting microbial resistance is of great significance for the rapid identification of pathogens and the rational selection of antibiotics in clinical practice.
[0004] At present, the clinical detection of drug-resistant genes mainly includes drug sensitivity tests, PCR (polymerase chain reaction), LAMP (loop-mediated isothermal amplification), mNGS (metagenomics next generation sequencing), etc. Among them, the traditional drug sensitivity method is based on bacterial culture, and the whole process takes 2-3 days to report the drug sensitivity results, with a long detection cycle and complicated operation; when multiple drug resistance mechanisms coexist, it is often complicated and difficult to judge, with poor specificity, and the test results are easily affected by the environment; LAMP is based on isothermal amplification. Although the detection time is short, the LAMP reaction is very limited by the flux. Usually, one reaction tube can only detect one target; the second-generation sequencing technology (NGS) has developed rapidly in recent years, with large detection flux and wide target coverage, but its operation is complicated, the detection cycle is long, and the entire analysis process is difficult to meet industry standards; probe-based fluorescence quantitative PCR, as the mainstream drug-resistant gene detection technology, has the advantages of multiple, low cost and high sensitivity. Currently, most of the technologies or products based on probe-based fluorescent PCR on the market only cover a few types of drug-resistant genes; in addition, probe-based PCR often requires the design of primers and probe sequences for each target, which will undoubtedly increase the complexity of the design, increase the cost of detection and aggravate the formation of non-specific products; limited by the number of fluorescent channels of the detection machine, probe-based PCR can often only cover 4-7 targets in one tube, limiting its multiple detection capabilities.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a nucleic acid composition, a kit and a detection method for detecting multiple drug-resistant genes. By establishing a multiple universal LNA probe fluorescent quantitative PCR method (MLQPCR), the detection method of the present invention has the characteristics of rapid detection, simple design, strong specificity, low cost and strong versatility, which can meet the needs of common clinical drug-resistant gene detection.
[0007] The present invention is achieved in that:
[0008] In the first aspect, the present invention provides a nucleic acid composition for detecting multiple drug-resistant genes, the nucleic acid composition comprising primers and LNA universal probes; the drug-resistant genes include VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1 and ERMB.
[0009] Among them, the nucleotide sequences of primers for amplifying VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1 and ERMB genes are shown in SEQ ID NOs: 1-32; the nucleotide sequences of LNA universal probes are shown in SEQ ID NOs: 33-36.
[0010] In order to solve the problems of small target coverage, unreasonable target setting, and low correlation between genotype and phenotype of some drug-resistant genes, the present invention selects 16 drug-resistant genes with high drug resistance and high clinical genotype and phenotype consistency as detection targets, namely VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1 and ERMB.
[0011] The primers for amplifying the above-mentioned drug-resistant gene include upstream primers and downstream primers, wherein the upstream primer consists of three parts: a Tag sequence that is reverse complementary to the LNA universal probe, a spacer sequence containing 4 bases, and a specific primer sequence that is completely complementary to the target sequence; the design of the downstream primer is the same as conventional PCR.
[0012] LNA (Locked Nucleic Acid) is usually modified on primers or probes because it can significantly improve the efficiency of Watson hydrogen bonding and the stability of DNA double strands. By increasing the Tm (melting temperature) value, the primers or probes have higher template binding ability; at the same time, it can achieve the design of shorter probe sequence length without changing its overall Tm value, thereby significantly enhancing the specificity of the probe. In order to improve the detection sensitivity, the present invention designs LNA probes and combines LNA probes with fluorescent quantitative PCR technology. In order to further save detection costs, shorten detection time, and simplify the operation process, the present invention combines multiple real-time fluorescent PCR technology based on multicolor fluorescent channels with universal LNA probe technology. Only 4 universal LNA probes are needed, and 16 drug-resistant genes can be qualitatively or semi-quantitatively detected in 4 tube reactions, so that the technology has the characteristics of simplicity, rapidity, high sensitivity, and high throughput, and further reduces the detection cost.
[0013] The LNA universal probe of the present invention is an oligonucleotide chain with a length of 12-14 bases, in which some nucleotides are modified with locked nucleic acid (LNA). The specific detection principle is as follows:
[0014] likeFigure 1 As shown, after the primer and probe are added to the system, the LNA probe will spontaneously bind to the Tag sequence of the upstream primer, and the upstream primer and the downstream primer will spontaneously bind to the template. Due to the presence of the spacer sequence, the binding of the LNA probe and the Tag sequence does not hinder the binding efficiency of the primer and the template. In the first cycle, due to the presence of a quenching group at the 3' end of the probe, the probe will not be extended, and only the upstream primer and the downstream primer will be extended in the system. At this time, the nucleotide chain is extended under the action of DNA polymerase, but it does not extend to the position of the fluorescent group, so no fluorescence is generated in the first cycle; in the second cycle, while the pairing occurs in the previous cycle, the downstream primer will bind to the complementary chain generated by the extension of the upstream primer in the previous cycle, and then extend under the action of DNA polymerase. Due to the 5'-3' exonuclease activity of the DNA polymerase, the fluorescent group at the 5' end of the LNA probe is hydrolyzed to generate fluorescence. In the third cycle and beyond, repeated denaturation, annealing and extension processes will produce more "semi-conservative replication chains", and more LNA probes will be hydrolyzed, resulting in exponential fluorescence growth. By collecting fluorescence, the amplification curve and CT value are obtained to determine whether the sample to be tested carries any of the 16 drug-resistant genes mentioned above.
[0015] In some embodiments, the 5' end of each LNA universal probe in the nucleic acid composition is labeled with a fluorescent reporter group, and the 3' end is labeled with a fluorescent quencher group; the fluorescent reporter groups include FAM, VIC, ROX and TAMRA, and the fluorescent quencher groups include BHQ1, BHQ2 and BHQ3.
[0016] It should be noted that the modified sites and number of modifications, the length of the spacer sequence, the length and base composition of the probe or tag sequence, and the concentrations of primers and probes in the present invention can be adjusted according to different targets and are not limited thereto.
[0017] In a second aspect, the present invention provides the use of the above-mentioned nucleic acid composition in the preparation of a kit for detecting multiple drug-resistant genes.
[0018] In some embodiments, the above applications include detecting VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1 and ERMB.
[0019] In a fourth aspect, the present invention provides a kit for detecting multiple drug-resistant genes, comprising the above-mentioned LNA universal probe and primers.
[0020] In a fifth aspect, the present invention also provides a method for detecting multiple drug-resistant genes for non-diagnostic purposes, which comprises: adding samples to a reaction system to carry out multiple real-time fluorescence quantitative PCR reactions; after the reaction is completed, analyzing the test results according to the amplification curve graph and Ct value to obtain the test results.
[0021] The above detection method is a multiple universal LNA probe fluorescence quantitative PCR method established by combining universal LNA probes with fluorescence quantitative PCR technology. The method uses four channels of FAM, VIC, TAMRA, and ROX to collect fluorescence. Since the targets of the same channel have similar PCR amplification efficiency, the present invention uses VANB, KPC, MECA and CTX-M-14 as representative targets of the four channels, and divides the above 16 drug-resistant genes into four groups, corresponding to the four detection channels, namely: FAM channel-VANA, VANB, VANC and VANM; VIC channel-KPC, OXA-23, NDM-1 and OXA-48; TAMRA channel-CTX-M-14, CTX-M-15, TEM-1 and ACRB; ROX-MECA, MCR-1, IMP-1 and ERMB.
[0022] In some embodiments, the primers and LNA universal probes corresponding to the above four detection channels are:
[0023] FAM channel - primers for amplifying VANA, VANB, VANC and VANM, and LNA universal probe, the sequences of which are shown in SEQ ID NO: 1-8 and SEQ ID NO: 33.
[0024] VIC channel - primers for amplifying KPC, OXA-23, NDM-1 and OXA-48, and LNA universal probe, the sequences of which are shown in SEQ ID NOs: 9-16 and SEQ ID NO: 34.
[0025] TAMRA channel-amplification primers and LNA universal probe for CTX-M-14, CTX-M-15, TEM-1 and ACRB, the sequences are shown in SEQ ID NO:17-24 and SEQ ID NO:36.
[0026] ROX channel-amplification primers for MECA, MCR-1, IMP-1 and ERMB, and LNA universal probe, the sequences are shown in SEQ ID NO:25-32 and SEQ ID NO:35.
[0027] The detection method provided by the present invention can be used to detect drug-resistant genes in multiple scenarios, such as Figure 2As shown in the figure, Figure A is to detect each target gene through separate reactions. In each reaction tube, each fluorescent channel only detects one target gene. By increasing the number of reaction tubes, the purpose of detecting multiple target genes with one LNA universal probe can be achieved; Figure B is to detect the total amount of genes in each fluorescent channel through a mixed reaction in one tube, which is suitable for methods that do not require quantification of each gene separately but detect the total amount of genes. Subsequently, the two strategies can be combined for detection according to actual needs, for example, a class of drug-resistant genes with consistent phenotypes (VANA, VANM, etc.) are detected with one channel, and the remaining channels are only used to detect a special target (such as MECA, etc.).
[0028] In multiplex PCR detection, the ratio of primers to LNA universal probes will affect the detection effect. In order to obtain better detection results, the inventors screened the concentrations of primers and LNA universal probes in the detection system.
[0029] In some embodiments, the molar concentration ratio of primer to LNA universal probe in the reaction system is: 4-6:3-6.
[0030] The molar concentration of primers / probes of different drug-resistant genes will also affect the detection effect. In order to obtain better detection effect, the inventors screened the concentrations of primers / probes of different drug-resistant genes in the detection system.
[0031] In some embodiments, the primers in the reaction system include a first primer combination, a second primer combination, a third primer combination and a fourth primer combination, the first primer combination includes primers for amplifying VANA, VANB, VANC and VANM; the second primer combination includes primers for amplifying KPC, OXA-23, NDM-1 and OXA-48; the third primer combination includes primers for amplifying CTX-M-14, CTX-M-15, TEM-1 and ACRB; the fourth primer combination includes primers for amplifying MECA, MCR-1, IMP-1 and ERMB; the molar concentration ratio of the first primer combination, the second primer combination, the third primer combination and the fourth primer combination is 4:4:5:6.
[0032] In some embodiments, the LNA universal probe in the reaction system includes a first LNA universal probe, a second LNA universal probe, a third LNA universal probe and a fourth LNA universal probe; the molar concentration ratio of the first LNA universal probe, the second LNA universal probe, the third LNA universal probe and the fourth LNA universal probe is 2:2:2:1.
[0033] In some embodiments, the kit also includes an amplification reagent, which contains DNA polymerase, dNTPs, Mg 2+ , PCR buffer.
[0034] In some embodiments, the reaction system is 20 μL: 10.0 μL amplification reagent, 5.9 μL primers and LNA universal probes, 1 μL template DNA, 3.1 μL enzyme-free water; the reaction procedure is: 95°C pre-denaturation for 30s; 95°C for 5s, 60°C for 30s, for a total of 40 cycles.
[0035] The present invention has the following beneficial effects:
[0036] (1) Low cost, economical and versatile
[0037] Since the present invention has the characteristics of high versatility, the cost of reaction tubes is greatly reduced. Correspondingly, only 4 LNA universal probes are needed for the detection of 16 drug-resistant genes, and the cost is much lower than the mainstream drug-resistant gene detection method in the field; at the same time, the present invention is applicable to the detection of all drug-resistant genes in clinical samples, and only specific primers need to be designed according to the target of interest, and there is no need to design expensive specific probes for each target, so the present invention is very economical and applicable.
[0038] (2) Reliable results and high sensitivity
[0039] The detection results of microbial resistance genes in 172 bronchoalveolar lavage fluid samples based on the present invention are completely consistent with the sequencing results; in addition, the present invention can detect resistance gene targets as low as 25 copies / μL. Therefore, the present invention can achieve rapid, accurate and sensitive detection of resistance genes, and has good prospects for clinical application.
[0040] (3) The detection method is flexible and pollution-free
[0041] Compared with the traditional PCR amplification method, the method of the present invention avoids contamination caused by opening the cover, and can detect specific drug-resistant genes with a low false positive rate. The present invention can directly determine whether the amplified product of the target gene exists based on the fluorescence curve of the probe, and does not involve any chemical reagents that are toxic to the human body. The entire detection process only takes 50 minutes to 1 hour, and is simple to operate, short in time, safe, and pollution-free. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0043] Figure 1 The detection principle of the detection method of the present invention;
[0044] Figure 2Schematic diagram of detection methods of the detection method of the present invention in different scenarios;
[0045] Figure 3 The test result of the partially positive test of tube 1 in the sample test in Example 3;
[0046] Figure 4 is the positive sequencing result of the FAM channel of tube 1 in Example 3;
[0047] Figure 5 This is the positive sequencing result of the VIC channel of tube 1 in Example 3;
[0048] Figure 6 is the positive sequencing result of the ROX channel of tube 1 in Example 3;
[0049] Figure 7 The test result of the partially positive sample in tube 2 in Example 3;
[0050] Figure 8 is the positive sequencing result of the FAM channel of tube 2 in Example 3;
[0051] Fig. 9 This is the positive sequencing result of the VIC channel of tube 2 in Example 3;
[0052] Fig.10 This is a test result diagram of a partially positive sample test of tube 3 in Example 3;
[0053] Fig.11 The test result of the partially positive test of tube 4 in the sample test in Example 3;
[0054] Fig.12 is the positive sequencing result of the TAMRA channel of tube 4 in Example 3;
[0055] Fig.13 This is the positive sequencing result of the VIC channel of tube 4 in Example 3;
[0056] Fig.14 The positive sequencing result of the ROX channel of tube 4 in Example 3;
[0057] Fig.15 Comparison of PCR amplification results of tag sequences of different lengths in Experimental Example 1;
[0058] Fig.16 The comparison results of the effect of the number of T bases in the spacer sequence on the PCR amplification efficiency in Experimental Example 2;
[0059] Fig.17 is the amplification curve of the FAM channel in Experimental Example 3;
[0060] Fig.18is the amplification curve of the VIC channel in Experimental Example 3;
[0061] Fig.19 is the amplification curve of the ROX channel in Experimental Example 3;
[0062] Fig. 20 is the amplification curve of the TAMRA channel in Experimental Example 3;
[0063] Fig.21 is the Ct value corresponding to the target at the concentrations of orthogonal primers and probes in the four fluorescence channels in Experimental Example 4;
[0064] Fig. 22 Comparison of amplification effects at different annealing temperatures in Experimental Example 5;
[0065] Fig.23 The amplification curve reaction standard curve diagram of the multiple PCR in Experimental Example 6;
[0066] Fig.24 It is the standard curve of the multiple PCR reaction in Experimental Example 6;
[0067] Fig.25 This is the amplification result diagram of the TRAMA channel selected separately in Experimental Example 6;
[0068] Fig.26 This is the repeatability test result in Experimental Example 7. DETAILED DESCRIPTION
[0069] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0070] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0071] Example 1
[0072] The design of primers and LNA universal probes involved in this embodiment mainly includes the following contents:
[0073] Primers were designed according to the conserved regions of the target sequences of drug-resistant genes, and the sequences of various pathogens were aligned using MEGA11.0 software. The target sequence of each target was determined based on the maximum number of pathogens covered. Primers for all tests of the present invention were designed, and the non-specific binding and secondary structure between primers were checked. All primers had similar annealing temperatures and were verified by dye-based QPCR, ensuring the normal amplification efficiency of the primer set and facilitating the optimization of each reaction parameter in the later stage. The design of the universal probe cannot be homologous to the target gene and should be avoided as much as possible to be homologous to other pathogenic microorganisms. All probe sequences are completely reverse complementary to the confirmed primer tag sequences (excluding the spacer sequence). All probes and primers were synthesized by a company in Shanghai. Table 1 shows the sequence information of primers and LNA universal probes for 16 drug-resistant genes, as shown below:
[0074] Table 1 Sequence information of primers and LNA universal probes for 16 drug resistance genes
[0075]
[0076]
[0077] Note: The number of bases indicates the base length of the amplicon; in the upstream primer F: the four bold Ts represent the spacer sequence, the 5' end on the left of the spacer sequence is the Tag sequence that is reverse complementary to the probe; the 3' end on the right is the target-specific amplification primer sequence.
[0078] "+" indicates that the next base is modified with LNA. The fluorescence quenching groups include BHQ1, BHQ2 and BHQ3. BHQ: Black hole quencher. FAM is 6-carboxyfluorescein; VIC is 5-VICphosphoramidite; ROX is Rhodamine 101; TAMRA is Tetramethylrhodamine.
[0079] Example 2
[0080] This embodiment provides a kit for detecting multiple drug resistance genes, which includes the primers and LNA universal probes in Example 1, and Probe qPCR SuperMix (Quanshijin Biotechnology Co., Ltd.).
[0081] Example 3
[0082] This example uses the kit of Example 2 to perform clinical sample testing, specifically as follows:
[0083] After nucleic acid was extracted from 172 bronchoalveolar lavage fluid samples from different batches, the nucleic acid samples were detected using the established real-time fluorescence quantitative PCR method.
[0084] In an eight-well plate or 96-well plate, mix the plasmid DNA or genomic DNA of the sample to be tested with the optimized primer-probe combination in Table 3 according to the proportion; TM 7 Real-Time PCR System instrument performs real-time quantitative fluorescence PCR detection, in which four channels of FAM, VIC, TAMRA, and ROX are used to collect fluorescence; according to the amplification curve and CT value analysis, it is judged whether the sample to be tested carries any drug-resistant gene. The drug-resistant genes corresponding to each channel are shown in Table 2:
[0085] Table 2 Fluorescence channels and detection tubes for the 16 drug-resistant genes
[0086] aisle Tube 1 Tube 2 Tube 3 Tube 4 FAM VANA VANB VANC VANM VIC KPC OXA-48 OXA-23 NDM-1 TAMRA CTX-M-14 CTX-M-15 TEM-1 ACRB ROX MECA MCR-1 IMP-1 ERMB
[0087] The optimized reaction program was: 95℃ pre-denaturation for 30s; 95℃ for 5s, 60℃ for 30s, for a total of 40 cycles. Probe qPCR SuperMix was used for amplification, and the optimized 20 μL PCR reaction system is shown in Table 3.
[0088] Table 3 Components of the multiplex QPCR reaction system
[0089] QPCR system components Volume (μL) FAM channel primer 0.4*2 FAM channel probe 0.6 VIC channel primers 0.5*2 VIC channel probe 0.6 ROX channel primers 0.4*2 ROX channel probe 0.6 TAMRA channel primers 0.6*2 TAMRA channel probe 0.3 template 1 Supermix Buffer 10 DEPC water 3.1
[0090] Note: The initial working concentration of primers and probes for all channels is 10 μM.
[0091] PCR tests were performed on 172 clinical samples using the above-mentioned amplification primers and probes. The detection status of the above-mentioned 16 drug-resistant bacteria in the samples was reflected based on the appearance of the amplification curve in the PCR test results, the type of fluorescent marker corresponding to the amplification curve, and the Ct value.
[0092] The test results are shown in Table 4:
[0093] Table 4 Clinical sample test results
[0094] Detection target Number of detected cases percentage OXA-23 90 52.23% ERMB 88 50.96% CTXM-14 59 34.39% KPC-1 54 31.21% TEM-1 41 23.57% CTXM-15 36 21.02% MECA 34 19.74% VANB 31 17.83% OXA-48 25 14.65% NDM-1 24 14.01% ACRB 23 13.38% VANC 20 11.46% VANA 19 10.83% VANM 12 7.01% MCR-1 8 4.46% IMP-1 5 3.18%
[0095] In the present invention, the results can be interpreted according to the amplification curve and the CT value. The criteria for judging a "positive" result are: the amplification curve starts normally, the Ct value of the target is reported as Ct <40, the negative control well is Ct ≥ 40, and the positive control well has a typical "S-type" amplification curve, which can be reported as "positive" and the result can be explained; the criteria for judging a "negative" result are: the target has no Ct value report or Ct ≥ 40, the negative control well is Ct ≥ 40, and the positive control well has a typical "S-type" amplification curve, which can be reported as "negative" and the result can be explained.
[0096] As shown in Table 4, only 5 patients did not detect any drug resistance gene, 56.4% of patients detected more than 3 drug resistance genes, the detection rate of carbapenem resistance gene OXA-23 and macrolide resistance gene ERMB was greater than 50%, and the sequencing results were compared with the results of the detection method of the present invention, and the negative and positive coincidence rates between the two were 100%. The specific sample amplification result diagram and sequencing diagram are shown in Figure 3-Figure 14 shown.
[0097] Figure 3 The results of partial positive detection of tube 1 in the sample detection. Among them, the FAM channel (VANA), VIC channel (KPC) and ROX channel (MECA) were positive, and the TAMRA channel (CTX-M-14) was not detected. The corresponding positive sequencing results are shown in Figure 4 , Figure 5 , Figure 6 .
[0098] Figure 7 This is the partial positive test result of tube 2 in the sample test. The FAM channel (VANB) and VIC channel (OXA-48) tested positive, and the TAMRA channel (CTX-M-15) and ROX channel (MCR-1) tested negative. The corresponding positive sequencing results are shown in Figure 8 and Fig. 9 .
[0099] Fig.10 This is the test result of tube 3 that is partially positive in the sample test, indicating that no drug resistance gene (VANC, OXA-23, TEM-1, IMP-1) was detected in the sample amplification results.
[0100] Fig.11 This is the partial positive test result of tube 4 in the sample test. Among them, the TAMRA channel (ACRB), VIC channel (NDM-1) and ROX channel (ERMB) were positive, and the FAM channel (VANM) was not detected. The corresponding positive sequencing results are shown in Fig.12 , Fig.13 , Fig.14 .
[0101] Experimental Example 1
[0102] This experiment is to verify the effect of different lengths of tag sequences on PCR amplification efficiency, as follows:
[0103] Taking the drug resistance gene VANB as an example, 10-16 random base sequences were selected and added to the 5' end of the upstream primer of VANB. The downstream primer sequence remained unchanged. Seven pairs of primers were designed and SYBR-GREEN dye PCR was performed to determine the effect of the tag sequence added alone on the PCR amplification efficiency. The primer sequences tested in this experiment are shown in Table 5.
[0104] Table 5 Upstream primer sequences with different lengths
[0105] Primers sequence length Add base number SEQ ID NO: VANB-F GGTATCTTCCGCATCCAT 18 0 3 1-VANB-F AATATAGGTATCTTCCGCATCCAT 24 6 37 2-VANB-F CGGATATAGGTATCTTCCGCATCCAT 26 8 38 3-VANB-F AGCGGATATAGGTATCTTCCGCATCCAT 28 10 39 4-VANB-F CCAGCGGATATAGGTATCTCCGCATCCAT 30 12 40 5-VANB-F TCCCAGCGATATAGGTATCTCCGCATCCAT 32 14 41 6-VANB-F CCTCCCAGCGGATATAGGTATCTCCGCATCCAT 34 16 42 7-VANB-F ACCCTCCCAGCGGATATAGGTATCTCCGCATCCAT 36 18 43
[0106] Depend on Fig.15 The amplification results show that the amplification effect is best when no additional bases are added to the 5' end of the upstream primer of VANB. The additional addition of 12-18 bases of Tag sequence has little effect on amplification and is used as the standard for subsequent Tag sequence length selection.
[0107] Experimental Example 2
[0108] This experiment verifies the effect of the number of T bases in the spacer sequence on the PCR amplification efficiency. The details are as follows:
[0109] Taking the KPC drug resistance gene as an example, different numbers of bases (2-6 T bases) were added as spacer sequences while the length of the Tag sequence remained unchanged to test the effect of the number of T bases in the spacer sequence on the PCR amplification efficiency. The primer sequences tested in this experimental example are shown in Table 6.
[0110] Table 6 Upstream primer sequences with different lengths of spacer sequences
[0111] Primers sequence length Add base number SEQ ID NO: KPC-F1 CATACCGACGCAGAAATGACTATGCCGTCGTCT 31 0 9 KPC-F2 CATACCGACGCAGATTAATGACTATGCCGTCGTCT 33 2 44 KPC-F3 CATACCGACGCAGATTTAATGACTATGCCGTCGTCT 35 3 45 KPC-F4 CATACCGACGCAGATTTTAATGACTATGCCGTCGTCT 36 4 46 KPC-F5 CATACCGACGCAGATTTTTAATGACTATGCCGTCGTCT 37 5 47 KPC-F6 CATACCGACGCAGATTTTTTAATGACTATGCCGTCGTCT 38 6 48
[0112] Fig.16 The amplification results showed that the fewer the number of bases in the spacer sequence, the better the amplification efficiency. For the KPC target, the effect of adding two additional T bases was the worst. Compared with adding 6 T bases, adding 3-5 additional T bases had the least effect on the amplification efficiency. Therefore, in the subsequent synthesis of the upstream primer, 4 T bases were selected as the spacer sequence.
[0113] Experimental Example 3
[0114] This experiment verified the effects of different numbers of LNA-modified bases and modification sites in the FAM, VIC, ROX, and TAMRA probe sequences, as follows:
[0115] VANB (FAM), KPC (VIC), CTX-M-14 (ROX) and MECA (TAMRA) were used as detection targets to explore the number of LNA-modified bases and modification sites in the probe sequence, and the Ct value and the fluorescence increment difference (△Rn) were used as the judgment basis. All probe sequences tested in this experiment are shown in Table 7.
[0116] Table 7 LNA probe sequences with different modification sites and numbers of modifications
[0117]
[0118]
[0119] Depend on Fig.17 The amplification curve of the FAM channel shows that the T-modified FAM-P1 has a higher PCR amplification efficiency than the CG-modified FAM-P2 probe. Fig.18 The amplification curve of the VIC channel shows that the CT-modified VIC-P1 has a higher PCR amplification efficiency than the T-modified VIC-P2 and G-modified VIC-P3 probes. Fig.19 The amplification curve of the ROX channel shows that the CGC-modified ROX-P1 probe and ROX-P2 probe have similar amplification efficiencies. Fig. 20 The amplification curve of the TAMRA channel shows that TAMRA-P1 has higher PCR amplification efficiency and ΔRn value than TAMRA-P2. In summary, the present invention selects the designed FAM-P1, VIC-P1, ROX-P1, and TAMRA-P1 sequences as universal LNA probes for four fluorescence channels.
[0120] Experimental Example 4
[0121] This experiment is to verify the amplification effect under different primer and probe concentrations. The detection method is the same as Example 3. The detection results are as follows: Fig.21 As shown:
[0122] Fig.21 It is the Ct value corresponding to the amplification of the target under the concentrations of orthogonal primers and probes in the four fluorescent channels. According to the test results, it can be found that the amplification effect of the primer and probe concentrations used in Example 3 is better, and the volumes of the primers and probes are: FAM channel (0.4μL, 0.6μL), ROX channel (0.4μL, 0.6μL), VIC channel (0.5μL, 0.6μL), TAMRA channel (0.6μL, 0.3μL).
[0123] Experimental Example 5
[0124] This experiment is to verify the amplification effect at the annealing temperature, and the detection method is the same as Example 3.
[0125] The best annealing temperature is determined based on the following criteria: taking the ΔCt value at 60°C as a reference, the sum of the ΔCt values of tubes 1 to 4 is the smallest.
[0126] Depend on Fig. 22 As shown in the figure, under the annealing condition of 56℃, the sum of the △Ct values of tubes 1 to 4 is greater than the sum of the △Ct values under the annealing condition of 60℃, indicating that 56℃ is not the optimal annealing temperature. Similarly, 58℃ and 62℃ are not the optimal annealing temperatures, and the sum of the △Ct values of 59℃ is slightly greater than the sum of the △Ct values of 60℃. If a target of a certain tube is detected separately, it can be detected according to the optimal annealing temperature of tube 1 (56℃), tube 2 (62℃), tube 3 (59℃), and tube 4 (56℃). When the annealing temperature of tubes 1-4 is 60℃, the sum of the Ct values of all targets is the lowest. Therefore, it can be found that 60℃ has a better amplification effect when used as a unified annealing temperature for the 4-tube multiplex reaction system.
[0127] Experimental Example 6
[0128] This experiment is for drawing the standard curve of multiple PCR reaction and determining the sensitivity:
[0129] The target gene amplicon was cloned into the PUC57 vector, and the resistance gene Amp was selected. The positive standard plasmid was constructed by gene synthesis. The DNA purity and concentration were measured with a micro-UV-visible spectrophotometer and diluted to 10 with TE buffer. 10 The plasmid standard was diluted in a concentration gradient, including 10 9 copies / μL, 10 8 copies / μL, 10 7 copies / μL, 10 6 copies / μL, 10 5 copies / μL, 104 copies / μL, 10 3 copies / μL, 10 2 copies / μL, 10 1 copies / μL and stored in a -20℃ refrigerator. The plasmid copy number calculation formula is: (6.02×10 23 copies / mol)×(concentration g / ml) / (MW g / mol)=X copies / ml, plasmid molecular weight (MW)=total length of recombinant plasmid (bp)×660(g / mol·bp).
[0130] 2.5×10 7 copies / μL-2.5×10 1A standard plasmid with a copy number of copies / μL was used as a template to perform 4-tube multiplex real-time fluorescence quantitative PCR amplification, and the amplification method was the same as in Example 3.
[0131] according to Fig.23 The standard curve was prepared by using the amplification curve results of the four targets in each reaction tube. The mixed standard plasmids with different copy numbers were used as templates for multiple PCR amplification. The standard curve of multiple PCR was drawn according to the Ct value. Fig.24 Due to the difference in fluorescence intensity and the interference between different fluorescent groups, the fluorescence signal increments of targets in different fluorescence channels in the same reaction tube vary greatly. For example, the MECA target in the TRAMA channel shows a lower fluorescence signal increment than other targets in the multiplex reaction system, but this does not mean that the amplification efficiency is poor (E=92.49%, R2=0.9951). For example Fig.25 The figure shows the amplification result of the TRAMA channel selected separately. The standard curve of the 4-tube multiplex reaction made with mixed plasmids shows that the established multiplex reaction system has good amplification effect, and most of the target R 2 The amplification efficiency was greater than 80%, and the minimum detection limit of all targets was 25 copies / μL.
[0132] Experimental Example 7
[0133] This experiment is a multiplex PCR reaction repeatability experiment:
[0134] For each tube of the multiplex reaction system, take 2.5×10 4 copies / μL, 2.5×10 5 copies / μL and 2.5×10 6 Four mixed plasmids with the same concentration of copies / μL were used as positive templates and PCR amplification was performed according to the method of the present invention. Three technical replicates were performed for each sample to determine the intra-group coefficient of variation. The above standard plasmid samples with different concentrations were repeated once a day for 3 days to determine the inter-group coefficient of variation.
[0135] like Fig.26 As shown, the repeatability experiment showed that the coefficient of variation within and between multiple channels of all targets was less than 5%, indicating that the method has good repeatability.
[0136] Experimental Example 8
[0137] This experiment is a multiplex PCR reaction specific experiment:
[0138] Clinically isolated Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas maltophilia, Cryptococcus neoformans and Serratia marcescens were tested. The results are shown in Table 8:
[0139] Table 8 Specificity test results of 10 clinically isolated microorganisms
[0140]
[0141]
[0142] Note: The numbers in the table are Ct values, and "-" means no amplification signal or no Ct value was determined. KP, Klebsiella pneumoniae; STM, Stenotrophomonas maltophilia; EC, Escherichia coli; PA, Pseudomonas aeruginosa; SA, Staphylococcus aureus; SP, Streptococcus pneumoniae; SM, Serratia marcescens; HI, Haemophilus influenzae; CA, Candida albicans; CN, Cryptococcus neoformans.
[0143] It can be seen from Table 8 that the drug-resistant genes detected for each strain are consistent with the drug-resistant phenotype of the bacteria, which proves that the present invention has good specificity.
[0144] In summary, the method of detecting 16 drug-resistant genes by multiplex fluorescence PCR technology based on universal LNA probes in the present invention is highly practical and economical. Only 4 fluorescent probes are needed to detect 16 targets, which greatly reduces the detection cost. In addition, the sensitivity, accuracy and other indicators of this method can meet clinical detection needs.
[0145] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A nucleic acid composition for detecting multiple drug resistance genes, characterized in that: The nucleic acid composition comprises a primer and an LNA universal probe; The drug resistance genes include VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1 and ERMB; The nucleotide sequences of the primers for amplifying the VANA gene are shown in SEQ ID NO: 1-2; The nucleotide sequences of the primers for amplifying the VANB gene are shown in SEQ ID NO:3-4; The nucleotide sequences of the primers for amplifying the VANC gene are shown in SEQ ID NOs: 5-6; The nucleotide sequences of the primers for amplifying the VANM gene are shown in SEQ ID NOs: 7-8; The nucleotide sequences of the primers for amplifying the KPC gene are shown in SEQ ID NOs: 9-10; The nucleotide sequences of the primers for amplifying the OXA-23 gene are shown in SEQ ID NOs: 11-12; The nucleotide sequences of the primers for amplifying the NDM-1 gene are shown in SEQ ID NOs: 13-14; The nucleotide sequences of the primers for amplifying the OXA-48 gene are shown in SEQ ID NOs: 15-16; The nucleotide sequences of the primers for amplifying the CTX-M-14 gene are shown in SEQ ID NOs: 17-18; The nucleotide sequences of the primers for amplifying the CTX-M-15 gene are shown in SEQ ID NOs: 19-20; The nucleotide sequences of the primers for amplifying the TEM-1 gene are shown in SEQ ID NOs: 21-22; The nucleotide sequences of the primers for amplifying the ACRB gene are shown in SEQ ID NOs: 23-24; The nucleotide sequences of the primers for amplifying the MECA gene are shown in SEQ ID NOs: 25-26; The nucleotide sequences of the primers for amplifying the MCR-1 gene are shown in SEQ ID NOs: 27-28; The nucleotide sequences of the primers for amplifying the IMP-1 gene are shown in SEQ ID NOs: 29-30; The nucleotide sequences of the primers for amplifying the ERMB gene are shown in SEQ ID NOs: 31-32; The nucleotide sequences of the LNA universal probes are shown in SEQ ID NOs: 33-36.
2. The nucleic acid composition according to claim 1, characterized in that The 5' ends of the LNA universal probes in the nucleic acid composition are each labeled with a fluorescent reporter group, and the 3' ends are each labeled with a fluorescent quencher group; the fluorescent reporter groups include FAM, VIC, ROX and TAMRA, and the fluorescent quencher groups include BHQ1, BHQ2 and BHQ3.
3. Use of the nucleic acid composition according to claim 1 or 2 in preparing a kit for detecting multiple drug-resistant genes.
4. The use according to claim 3, characterized in that: The applications include detection of VANA, VANB, VANC, VANM, KPC, OXA-23, NDM-1, OXA-48, CTX-M-14, CTX-M-15, TEM-1, ACRB, MECA, MCR-1, IMP-1, and ERMB.
5. A kit for detecting multiple drug resistance genes, characterized in that: The kit comprises the LNA universal probe and primers according to claim 1 or 2.
6. A method for detecting multiple drug resistance genes for non-diagnostic purposes, characterized in that: include: The samples are added into the reaction system to carry out multiplex fluorescence quantitative PCR reaction. After the reaction is completed, the test results are analyzed according to the amplification curve and Ct value to obtain the test results.
7. The method according to claim 6, characterized in that The molar concentration ratio of the primer to the LNA universal probe in the reaction system is 4-6:3-6.
8. The method according to claim 6, characterized in that The primers in the reaction system include a first primer combination, a second primer combination, a third primer combination and a fourth primer combination, wherein the first primer combination includes primers for amplifying VANA, VANB, VANC and VANM; the second primer combination includes primers for amplifying KPC, OXA-23, NDM-1 and OXA-48; the third primer combination includes primers for amplifying CTX-M-14, CTX-M-15, TEM-1 and ACRB; The fourth primer combination includes primers for amplifying MECA, MCR-1, IMP-1, and ERMB; The molar concentration ratio of the first primer combination, the second primer combination, the third primer combination and the fourth primer combination is 4:4:5:
6.
9. The kit according to claim 6, characterized in that The LNA universal probes in the kit include a first LNA universal probe, a second LNA universal probe, a third LNA universal probe and a fourth LNA universal probe; The molar concentration ratio of the first LNA universal probe, the second LNA universal probe, the third LNA universal probe and the fourth LNA universal probe is 2:2:2:
1.
10. The method according to any one of claims 6 to 9, characterized in that: The reaction system is 20 μL: 10.0 μL amplification reagent, 5.9 μL primers and LNA universal probe, 1 μL template DNA, and 3.1 μL enzyme-free water; The reaction procedure is: pre-denaturation at 95°C for 30s; 95°C for 5s, 60°C for 30s, for a total of 40 cycles.
